Figure 6.
Ulixertinib inhibits tumor growth in the CHLA255-Fluc xenograft NB mouse model. (A) Treatment strategy of the xenograft NB mouse model. (B) Bioluminescent imaging photos of CHLA255 xenograft NB mice from the DMSO control group and the ulixertinib treated group (50 mg/kg). (C) The values of bioluminescent imaging of xenograft NB mice were monitored during tumor growth. (D) The survival rate of CHLA255 xenograft NB mice treated with ulixertinib and control. Statistical analysis was performed by a Log-rank test. (χ2 = 5.213; p = 0.0224).